NVX-CoV2540 / Novavax - LARVOL DELTA

COVID-19 vaccine (NVX-CoV2373 and NVX-CoV2540) doses and virus strain match impact sex- and age-specific immunity and protection in mice. (PubMed, Vaccine) - "Immunization with the BA.5 booster improved antibody responses and B and T cell frequencies in both adults and aged mice, eliminating sex and age differences in immunity and protection from SARS-CoV-2 challenge. These data highlight that there are limits to cross-protective immunity, particularly among males and aged individuals, that can be improved through booster doses that more closely match the challenge SARS-CoV-2 virus."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov) - P3 | N=1340 | Completed | Sponsor: Novavax | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial. (PubMed, Lancet Infect Dis) - P3 | "All three coprimary endpoints were met in part 2 of the ongoing 2019nCoV-311 study. These data support the development of monovalent and/or bivalent vaccines for the most currently circulating variants, to optimise protection. With no new safety findings, further investigation of omicron-based subvariant vaccines is supported by the evidence."

Head-to-Head • Journal • P3 data • P3 data: top line • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Phase 3 Boosting Study for the SARS-CoV-2 rS Variant Vaccines (clinicaltrials.gov) - P3 | N=1340 | Active, not recruiting | Sponsor: Novavax | Trial completion date: Jul 2023 ➔ Feb 2024

Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases